Related Experiment Video
Updated: May 3, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Ketogenic diet efficacy in the treatment of intractable epileptic spasms
Husam R Kayyali1, Megan Gustafson1, Tara Myers1
1Division of Neurology, Department of Pediatrics, Children's Mercy Hospitals and Clinics, University of Missouri in Kansas City, Missouri.
Insights
The ketogenic diet effectively controlled epileptic spasms in infants who did not respond to traditional medications. This dietary therapy also improved quality of life and electroencephalography results in these challenging cases.
Area of Science:
- Neurology
- Pediatric Neurology
- Metabolic Therapies
Background:
- Epileptic spasms are a severe form of epilepsy in infants.
- Refractory cases often fail to respond to conventional antiepileptic drugs.
- The ketogenic diet is an established therapy for drug-resistant epilepsy.
Purpose of the Study:
- To evaluate the efficacy of the ketogenic diet for infantile epileptic spasms.
- To assess seizure control and quality of life improvements.
- To determine the safety and effectiveness in medication-refractory cases.
Main Methods:
- Prospective, case-based study of infants with epileptic spasms.
- Inclusion criteria: refractory spasms despite antiepileptic drugs and hypsarrhythmia/encephalopathy on EEG.
- Diet efficacy assessed via clinical visits, phone communication, and EEG; quality of life via caregiver reports.
Main Results:
- 70% of 20 infants achieved >50% seizure reduction within 3 months on the ketogenic diet.
- Seizure reduction was maintained at 12 and 24 months.
- Significant improvements in electroencephalography (60%) and caregiver-reported quality of life (63% within 1 month) were observed.
Conclusions:
- The ketogenic diet is a safe and effective treatment option for infants with drug-resistant epileptic spasms.
- It offers a viable alternative when traditional antiepileptic medications fail.
- Positive impacts on seizure frequency, EEG, and quality of life support its use.
Objective:
To determine the efficacy of the ketogenic diet in controlling epileptic spasms after failing traditional antiepileptic medication therapy.
Methods:
This is a prospective, case-based study of all infants with epileptic spasms who were referred for treatment with the ketogenic diet at our hospital between 2009 and 2012. All subjects continued to have epileptic spasms with evidence of hypsarrhythmia or severe epileptic encephalopathy on electroencephalography despite appropriate medication treatments. The diet efficacy was assessed through clinic visits, phone communications, and electroencephalography. Quality of life improvement was charted based on the caregiver's perspective.
Results:
Twenty infants (15 males) were included in the study. The mean age at seizure onset was 4.5 months. Age at ketogenic diet initiation was 0.3 to 2.9 years (mean 1.20, standard deviation 0.78). Fifteen patients had epileptic spasms of unknown etiology; three had perinatal hypoxic ischemic encephalopathy, one had lissencephaly, and one had STXBP1 mutation. Fifteen infants failed to respond to adrenocorticotropin hormone and/or vigabatrin before going on the ketogenic diet. Three months after starting the diet, >50% seizure reduction was achieved in 70% of patients (95% CI 48-86). These results were maintained at 6- and 12-month intervals. All eight of the patients followed for 24 months had >50% seizure reduction (95% CI 63-100). At least 90% seizure reduction was reported in 20% of patients at 3 months (95% CI 7-42), 22% (95% CI 8-46) at 6 months, and 35% (95% CI 17-59) at 12 months. The majority of patients (63%) achieved improvement of their spasms within 1 month after starting the diet. Sixty percent of patients had electroencephalographic improvement. All caregivers reported improvement of the quality of life at the 3-month visit (95% confidence interval 81-100). This ratio was 94% at 6 months (95% CI 72-99) and 82% at 12 months (95% CI 58-95).
Conclusion:
The ketogenic diet is a safe and potentially effective method of treatment for patients with epileptic spasms, especially those who do not respond to customary medication therapies.
More Related Videos
07:35Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...